Online inquiry

IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ10116MR)

This product GTTS-WQ10116MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_002286.6
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3902
UniProt ID	P18627

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10116MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ952MR	IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ABBV-323
GTTS-WQ6017MR	IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CNTO 1275
GTTS-WQ6267MR	IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CR-6261
GTTS-WQ13671MR	IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	RC18
GTTS-WQ5794MR	IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	cetuximab-IR700
GTTS-WQ3703MR	IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	BAY 2287409
GTTS-WQ5759MR	IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	CetuxiMab-GEX
GTTS-WQ10013MR	IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	KRN-23

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST